Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cleveland Clinic Foundation, U.S.
Solid cancer dosage linearly related to mean steady-state plasma concentrations of phenoxodiol
July 4th, 2006
Scientists suggested a linear relationship between dosage and mean steady-state plasma concentrations of phenoxodiol in solid cancer. According to a study from the United States, "Phenoxodiol is a multi-pathway initiator of apoptosis with broad anti-tumor activity and high specificity for tumor cells. Its biochemical effects are particularly suited to reversal of chemo-resistance, and the drug is being developed as a chemo-sensitizer of standard chemotherapeutics in solid cancers." "This phase I, single-center trial was conducted to test a continuous intravenous dosing regimen of phenoxodiol in patients with late-stage, solid tumors to determine...
Source: Pharma Law Weekly (2006-07-04)
|
